BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024
August 07 2024 - 7:00AM
BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and
cell-derived therapeutics for the treatment of cardiovascular and
pulmonary diseases, today announced it will provide a corporate
update and report its financial results for the three months ended
June 30, 2024 by conference call on Tuesday, August 13, 2024 at
4:30 PM ET. Following management’s formal remarks, there will be a
question-and-answer session.
Participants can register for the conference by navigating to
https://dpregister.com/sreg/10191562/fd3d36338a. Please note that
registered participants will receive their dial-in number upon
registration. For those who have not registered, to listen to the
call by phone, interested parties within the U.S. should call
1-833-316-0559 and international callers should call
1-412-317-5730. All callers should dial in approximately 10 minutes
prior to the scheduled start time and ask to be joined into the
BioCardia call. The conference call will also be available through
a live webcast, which can be accessed through the following link:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=BLDb4kwc
A webcast replay of the call will be available approximately one
hour after the end of the call at the following link:
https://services.choruscall.com/ccforms/replay.html. A telephonic
replay of the call will be available and may be accessed by calling
1-877-344-7529 (domestic), 1-412-317-0088 (international) or
855-669-9658 (Canada) by using access code 6578627.
About BioCardia®BioCardia,
Inc., headquartered in Sunnyvale, California, is global leader
in cellular and cell-derived therapeutics for the treatment of
cardiovascular and pulmonary disease. CardiAMP® autologous and
CardiALLO™ allogeneic cell therapies are the Company’s
biotherapeutic platforms with three clinical stage product
candidates in development. These therapies are enabled by its
Helix™ biotherapeutic delivery and Morph® vascular navigation
product platforms. For more information visit
www.biocardia.com.
MEDIA CONTACT:
Miranda Peto, Marketing / Investor Relations
mpeto@biocardia.com
(650) 226-0120
INVESTOR CONTACT:
David McClung, Chief Financial Officer
investors@biocardia.com
(650) 226-0120
BioCardia (NASDAQ:BCDA)
Historical Stock Chart
From Jul 2024 to Aug 2024
BioCardia (NASDAQ:BCDA)
Historical Stock Chart
From Aug 2023 to Aug 2024